Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Fineline Cube Aug 20, 2026
Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Fineline Cube Aug 20, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Drug

GSK’s Jemperli Receives FDA Approval for First-Line Treatment of Advanced Endometrial Cancer

Fineline Cube Aug 1, 2023

GSK plc (NYSE: GSK), a major UK pharmaceutical company, has announced that the US Food...

Company Drug

Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna

Fineline Cube Aug 1, 2023

US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA)...

Company Deals

Mindray Bio-Medical Electronics to Acquire Majority Stake in DiaSys Diagnostic Systems

Fineline Cube Aug 1, 2023

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical device company based in...

Company Deals

EnChannel Secures RMB 200 Million in Series A Funding to Advance Electrophysiology Solutions

Fineline Cube Aug 1, 2023

EnChannel Medical, a Guangzhou-based electrophysiology platform company, has reportedly secured RMB 200 million (USD 28...

Company Deals

Sinovation Secures Over RMB 100 Million in Series D+ Financing for Neurosurgery Innovations

Fineline Cube Aug 1, 2023

Beijing-based Sinovation (Beijing) Medical Technology Co., Ltd., a leader in neurosurgery diagnosis, minimally invasive procedure...

Company Medical Device

Peijia Medical Commences Clinical Study for Taurus Trio TAVR System with First Patient Enrollment

Fineline Cube Aug 1, 2023

Peijia Medical Ltd (HKG: 9996) has announced the enrollment of the first patient in a...

Company Drug

RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval

Fineline Cube Aug 1, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...

Company R&D

Hainan Boao Lecheng Partners with BeiGene to Boost Medical Tourism and Biotech Innovation

Fineline Cube Aug 1, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a partnership with...

Company Drug

Jiangsu Hengrui’s Camrelizumab and Apatinib Combo Accepted for FDA Review for HCC Treatment

Fineline Cube Aug 1, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the US Food and Drug...

Company Drug

Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment

Fineline Cube Aug 1, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has...

Company Drug

Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study

Fineline Cube Aug 1, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase...

Company Drug

Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China

Fineline Cube Aug 1, 2023

China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...

Company

WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023

Fineline Cube Aug 1, 2023

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for...

Company

HutchMed Ltd Reports 164% Revenue Growth and Clinical Updates for H1 2023

Fineline Cube Aug 1, 2023

China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the...

Policy / Regulatory

Shanghai HSA Unveils Measures to Boost Access to Innovative Drugs and Devices

Fineline Cube Aug 1, 2023

The Healthcare Security Administration (HSA) in Shanghai has recently released a set of Measures aimed...

Company

Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results

Fineline Cube Jul 31, 2023

Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023,...

Company Medical Device

MicroPort MedBot’s SkyWalker Orthopedic Surgery Robot Gains TGA Approval in Australia

Fineline Cube Jul 31, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Policy / Regulatory

CDE Releases Draft Guidelines for Clinical Pharmacology Research of Chemical Modified Drugs

Fineline Cube Jul 31, 2023

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Pharmacological Research...

Company Deals

Baidu Health Partners with GSK for Shingles Disease Education Programs in China

Fineline Cube Jul 31, 2023

China Internet giant Baidu’s Health Internet Hospital unit has entered into a strategic partnership with...

Company Drug

Transcenta Holdings Gets CDE Approval for Phase II Study of TST002 for Bone Density

Fineline Cube Jul 31, 2023

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval...

Posts pagination

1 … 539 540 541 … 710

Recent updates

  • China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year
  • CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
  • Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light
  • VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation
  • Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Company

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030

Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.